All In Biotech

Drug Trial Radar · NCT02001623

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

Last checked: Nov 20, 2026Latest source record: Dec 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

195

Actual

Start

Nov 30, 2013

Primary completion

May 2, 2019

Study completion May 2, 2019

Sponsor

Lead sponsor
Seagen Inc.Pfizer (PFE)
Sponsor type
Industry
Collaborators
Genmab
First posted
Dec 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.

Conditions

  • Ovary Cancer
  • Cervix Cancer
  • Endometrium Cancer
  • Bladder Cancer
  • Prostate Cancer (CRPC)
  • Esophagus Cancer
  • Lung Cancer(NSCLC)
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions

  • Tisotumab Vedotin (HuMax-TF-ADC)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Part: Evaluation of Treatment-Emergent Adverse EventsTime frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.
  2. Dose Expansion Part: Evaluation of Treatment-Emergent Adverse EventsTime frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California Irvine Medical Center (UCIMC)

    Orange, California

  • Yale Cancer Center

    New Haven, Connecticut

  • University of Miami

    Miami, Florida

  • University Gynecologic Oncology

    Atlanta, Georgia

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Saint-Luc University Hospital

    Brussels, Belgium

  • CHU de Liège

    Liège, Belgium

  • CHU UCL Namur - Sainte Elisabeth

    Namur, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Antwerpen, Belgium

  • Universitair Ziekenhuis Leuven

    Leuven, Flemish Brabant, Belgium

  • Grand Hôpital de Charleroi

    Charleroi, Hainaut, Belgium

  • Centre Hospitalier Universitaire Ambroise Paré

    Mons, Hainaut, Belgium

  • CHU UCL Namur - site Godinne

    Yvoir, Namur, Belgium

  • Rigshospitalet, Copenhagen University Hospital

    Copenhagen, Denmark

  • Herlev and Gentofte Hospital

    Herlev, Denmark

  • Lungemedicinska Kliniken

    Linköping, Sweden

  • Karolinska Universitetssjukhuset

    Stockholm, Solna, Sweden

  • Beatson Cancer Centre

    Glasgow, United Kingdom

  • Guys hospital

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • The Leeds Teaching Hospitals NHS Trust

    Leeds, England, United Kingdom

  • University College London Hospitals

    London, England, United Kingdom

  • Sarah Cannon Research Institute - London

    London, England, United Kingdom

  • Newcastle Hospitals NHS Foundation Trust

    Newcastle upon Tyne, Newcastle, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, United Kingdom

  • Velindre NHS Trust

    Cardiff, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.